Cargando…

Unexpectedly durable palliation of metastatic olfactory neuroblastoma using anti-angiogenic therapy with Bevacizumab

Olfactory neuroblastomas (ONBs) are rare malignant tumors that arise from olfactory epithelium and typically present with symptoms attributable to locally invasive disease. Kadish radiographic staging and Hyams' histopathologic grading are prognostic. Overall survival rates, averaging 60–70% at...

Descripción completa

Detalles Bibliográficos
Autores principales: Dunbar, Erin M., Pumphrey, Phyllis K., Bidari, Sharat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PAGEPress Publications 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3401161/
https://www.ncbi.nlm.nih.gov/pubmed/22826790
http://dx.doi.org/10.4081/rt.2012.e33
_version_ 1782238576264609792
author Dunbar, Erin M.
Pumphrey, Phyllis K.
Bidari, Sharat
author_facet Dunbar, Erin M.
Pumphrey, Phyllis K.
Bidari, Sharat
author_sort Dunbar, Erin M.
collection PubMed
description Olfactory neuroblastomas (ONBs) are rare malignant tumors that arise from olfactory epithelium and typically present with symptoms attributable to locally invasive disease. Kadish radiographic staging and Hyams' histopathologic grading are prognostic. Overall survival rates, averaging 60–70% at 5 years, remain limited by high rates of delayed loco-regional and distant progression. At initial presentation, the available evidence supports the use of multimodality therapy, historically surgery and radiation, to improve disease-free and overall survival. At recurrence/progression, the available evidence supports the use of therapy to improve disease control and symptoms (palliation), but patient heterogeneity dictates individualization of modalities. Although the ideal use of chemotherapy as a modality remains undefined, the available evidence supports it use, historically platinum-based, for palliation. However, recent insights into the molecular-genetic aberrations of ONBs, coupled with the emergence chemotherapeutic agents capable of targeting such aberrations, suggest an expanded role. The authors report a case of a 60 years-old man, heavily pre-treated for metastatic ONB, presenting with profound central-nerve-system and head-and-neck symptoms. He experienced unexpectedly durable palliation with Bevacizumab anti-angiogenic therapy. Additionally, he experienced localized palliation with an Ommaya reservoir. The authors review the literature regarding historical and emerging therapies for ONB to emphasize the needs for individualization and translational-clinical studies.
format Online
Article
Text
id pubmed-3401161
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher PAGEPress Publications
record_format MEDLINE/PubMed
spelling pubmed-34011612012-07-23 Unexpectedly durable palliation of metastatic olfactory neuroblastoma using anti-angiogenic therapy with Bevacizumab Dunbar, Erin M. Pumphrey, Phyllis K. Bidari, Sharat Rare Tumors Case Report Olfactory neuroblastomas (ONBs) are rare malignant tumors that arise from olfactory epithelium and typically present with symptoms attributable to locally invasive disease. Kadish radiographic staging and Hyams' histopathologic grading are prognostic. Overall survival rates, averaging 60–70% at 5 years, remain limited by high rates of delayed loco-regional and distant progression. At initial presentation, the available evidence supports the use of multimodality therapy, historically surgery and radiation, to improve disease-free and overall survival. At recurrence/progression, the available evidence supports the use of therapy to improve disease control and symptoms (palliation), but patient heterogeneity dictates individualization of modalities. Although the ideal use of chemotherapy as a modality remains undefined, the available evidence supports it use, historically platinum-based, for palliation. However, recent insights into the molecular-genetic aberrations of ONBs, coupled with the emergence chemotherapeutic agents capable of targeting such aberrations, suggest an expanded role. The authors report a case of a 60 years-old man, heavily pre-treated for metastatic ONB, presenting with profound central-nerve-system and head-and-neck symptoms. He experienced unexpectedly durable palliation with Bevacizumab anti-angiogenic therapy. Additionally, he experienced localized palliation with an Ommaya reservoir. The authors review the literature regarding historical and emerging therapies for ONB to emphasize the needs for individualization and translational-clinical studies. PAGEPress Publications 2012-06-12 /pmc/articles/PMC3401161/ /pubmed/22826790 http://dx.doi.org/10.4081/rt.2012.e33 Text en ©Copyright E.M. Dunbar et al., 2012 This work is licensed under a Creative Commons Attribution NonCommercial 3.0 License (CC BY-NC 3.0). Licensee PAGEPress, Italy
spellingShingle Case Report
Dunbar, Erin M.
Pumphrey, Phyllis K.
Bidari, Sharat
Unexpectedly durable palliation of metastatic olfactory neuroblastoma using anti-angiogenic therapy with Bevacizumab
title Unexpectedly durable palliation of metastatic olfactory neuroblastoma using anti-angiogenic therapy with Bevacizumab
title_full Unexpectedly durable palliation of metastatic olfactory neuroblastoma using anti-angiogenic therapy with Bevacizumab
title_fullStr Unexpectedly durable palliation of metastatic olfactory neuroblastoma using anti-angiogenic therapy with Bevacizumab
title_full_unstemmed Unexpectedly durable palliation of metastatic olfactory neuroblastoma using anti-angiogenic therapy with Bevacizumab
title_short Unexpectedly durable palliation of metastatic olfactory neuroblastoma using anti-angiogenic therapy with Bevacizumab
title_sort unexpectedly durable palliation of metastatic olfactory neuroblastoma using anti-angiogenic therapy with bevacizumab
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3401161/
https://www.ncbi.nlm.nih.gov/pubmed/22826790
http://dx.doi.org/10.4081/rt.2012.e33
work_keys_str_mv AT dunbarerinm unexpectedlydurablepalliationofmetastaticolfactoryneuroblastomausingantiangiogenictherapywithbevacizumab
AT pumphreyphyllisk unexpectedlydurablepalliationofmetastaticolfactoryneuroblastomausingantiangiogenictherapywithbevacizumab
AT bidarisharat unexpectedlydurablepalliationofmetastaticolfactoryneuroblastomausingantiangiogenictherapywithbevacizumab